Latest news and press releases about MapLight Therapeutics, Inc. (MPLT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.
Price
| Price | $11.40 |
| Market Cap | $484M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.66 |
| EV / EBITDA | -4.56 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -35.16% |
| Return on Invested Capital | -36.43% |
| Return on Assets | -33.61% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BRTX · DWTX · EDSA · ERNA · IMRN · LPCN · OSRH
Explore sector: Healthcare · Biotechnology
More sections of MPLT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks